Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to Assess the Safety and Immunogenicity of a Booster Vaccination With an Adapted Recombinant Protein RBD Fusion Homodimer Candidate Against SARS-CoV-2, in Adults Vaccinated Against COVID-19

NCT06181292 is registered in ClinicalTrials.gov with Hipra Scientific, S.L.U as lead sponsor.

NCT NCT06181292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06181292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to Assess the Safety and Immunogenicity of a Booster Vaccination With an Adapted Recombinant Protein RBD Fusion Homodimer Candidate Against SARS-CoV-2, in Adults Vaccinated Against COVID-19
Lead sponsor
Hipra Scientific, S.L.U
Phase
Phase 2/3
Overall status
Completed
Start date
November 15, 2023
Completion date
June 17, 2024
Enrollment
913 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov2 infection